How should clinicians and patients choose antihyperglycemic agents? An evidence-based approach

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The choice of antihyperglycemic agents has become more complex as new drug classes have appeared and evidence about their efficacy and safety accumulates. Unfortunately, direct and fair comparisons are lacking and the clinician and patient are left to decide among agents with different safety and burden profiles. Furthermore, the relative efficacy of these agents beyond their ability to lower hemoglobin A 1c - that is, in their ability to reduce the risk of diabetes complications - remains uncertain. In this sea of uncertainty, interests other than those of the patient actively shape choices. It is our expectation that better evidence, better policy and better decisions will eventually become routine in the care of patients with diabetes. Copyright by Medycyna Praktyczna, 2011.

Original languageEnglish (US)
Pages (from-to)208-212
Number of pages5
JournalPolskie Archiwum Medycyny Wewnetrznej
Volume121
Issue number6
StatePublished - 2011

Fingerprint

Hypoglycemic Agents
Hemoglobin A
Safety
Diabetes Complications
Oceans and Seas
Uncertainty
Patient Care
Pharmaceutical Preparations

Keywords

  • Antihyperglycemic agents
  • Clinical decision making
  • Patient-centered care
  • Type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine

Cite this

@article{ca13501a380340e4b73ccabb6f01af3d,
title = "How should clinicians and patients choose antihyperglycemic agents? An evidence-based approach",
abstract = "The choice of antihyperglycemic agents has become more complex as new drug classes have appeared and evidence about their efficacy and safety accumulates. Unfortunately, direct and fair comparisons are lacking and the clinician and patient are left to decide among agents with different safety and burden profiles. Furthermore, the relative efficacy of these agents beyond their ability to lower hemoglobin A 1c - that is, in their ability to reduce the risk of diabetes complications - remains uncertain. In this sea of uncertainty, interests other than those of the patient actively shape choices. It is our expectation that better evidence, better policy and better decisions will eventually become routine in the care of patients with diabetes. Copyright by Medycyna Praktyczna, 2011.",
keywords = "Antihyperglycemic agents, Clinical decision making, Patient-centered care, Type 2 diabetes",
author = "Montori, {Victor Manuel} and James Deming and Shah, {Nilay D}",
year = "2011",
language = "English (US)",
volume = "121",
pages = "208--212",
journal = "Polskie Archiwum Medycyny Wewnetrznej",
issn = "0032-3772",
publisher = "Medycyna Praktyczna",
number = "6",

}

TY - JOUR

T1 - How should clinicians and patients choose antihyperglycemic agents? An evidence-based approach

AU - Montori, Victor Manuel

AU - Deming, James

AU - Shah, Nilay D

PY - 2011

Y1 - 2011

N2 - The choice of antihyperglycemic agents has become more complex as new drug classes have appeared and evidence about their efficacy and safety accumulates. Unfortunately, direct and fair comparisons are lacking and the clinician and patient are left to decide among agents with different safety and burden profiles. Furthermore, the relative efficacy of these agents beyond their ability to lower hemoglobin A 1c - that is, in their ability to reduce the risk of diabetes complications - remains uncertain. In this sea of uncertainty, interests other than those of the patient actively shape choices. It is our expectation that better evidence, better policy and better decisions will eventually become routine in the care of patients with diabetes. Copyright by Medycyna Praktyczna, 2011.

AB - The choice of antihyperglycemic agents has become more complex as new drug classes have appeared and evidence about their efficacy and safety accumulates. Unfortunately, direct and fair comparisons are lacking and the clinician and patient are left to decide among agents with different safety and burden profiles. Furthermore, the relative efficacy of these agents beyond their ability to lower hemoglobin A 1c - that is, in their ability to reduce the risk of diabetes complications - remains uncertain. In this sea of uncertainty, interests other than those of the patient actively shape choices. It is our expectation that better evidence, better policy and better decisions will eventually become routine in the care of patients with diabetes. Copyright by Medycyna Praktyczna, 2011.

KW - Antihyperglycemic agents

KW - Clinical decision making

KW - Patient-centered care

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=79959553833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959553833&partnerID=8YFLogxK

M3 - Article

C2 - 21694685

AN - SCOPUS:79959553833

VL - 121

SP - 208

EP - 212

JO - Polskie Archiwum Medycyny Wewnetrznej

JF - Polskie Archiwum Medycyny Wewnetrznej

SN - 0032-3772

IS - 6

ER -